DND....my interpretation of Masila's comment below is that all patients, regardless of treatment, opted to continue being dosed beyond 104 weeks. Placebo continue on placebo. Apabetalone continue on apabetalone. It's blinded, so sound like all ~2400 patients (minus drop outs, deaths, etc) are continuing beyong 104 weeks.

BDAZ

“Apparently all patients interviewed want to stay on the treatment.  Some have been on close to 36 months.  That speaks volumes to me!”